IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare two strategies of de novo donor specific
antibodies (DSA) and antibody-mediated rejection (AMR) prevention in renal transplant
recipients: high dose intravenous immunoglobulin (IVIG)/rituximab regimens versus rituximab
alone.